SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Keith R. who wrote (66)11/5/1997 10:47:00 AM
From: Michael C. Woodward  Read Replies (1) | Respond to of 534
 
Thanks for your valuable input. I believe that the presentation to Hambricht & Quist will be a critical point for Bioject. Let's hope H&Q responds favorably.



To: Keith R. who wrote (66)11/9/1997 7:42:00 PM
From: geewiz  Read Replies (1) | Respond to of 534
 
Keith,

I share your expectations of pharmaceutical company marketing agreements. I have been asking the company about this for many years.
Prior to the Elan agreement these company's just didn't have the confidence that BJCT would be a survivor; Elan's partnership changes this all.

In answer to my question on the comming agreements all I have learned is that several are presently in the legal department.

Good luck, art


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News